Evidence-Based Medical News

Mode

All Infectious Disease Oncology Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Gastroenterology Primary Care & Family Medicine Nutrition & Obesity Medicine Orthopedics & Sports Medicine OB/GYN & Women's Health Radiology & Imaging Genetics & Precision Medicine Pulmonology & Critical Care Anesthesiology & Pain Medicine Physical Medicine & Rehab Nephrology Hematology Urology Ophthalmology Dermatology Emergency Medicine Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Text Size

Log in / Sign up

Overweight or Obesity

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Overweight or Obesity

7 trials tracked for Overweight or Obesity: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 4686 citations.

7Trials tracked

1Phase 3 & 4

0Recruiting

1With published results

Phase distribution

Phase 3 1 Phase 2 2 Other / NA 4

Phase 3 STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity Completed · 4,686 cited
Phase 2 Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese Completed
Phase 2 Adaptive Nutrition and Exercise Weight Loss (A-NEW) Study Completed
N/A A Virtual Cardiometabolic Health Program for African Immigrants: The Afro-DPP Program Completed
N/A A 6-month Observational Study on Combined Oral Contraceptives and Body Weight in Pre-Menopausal Women With Overweight or Obesity Completed
N/A eMOTION Formative Study Completed

Show 1 more trials

N/A Indigenous Supported Agriculture "Go Healthy" Completed

Showing the 7 most-cited and recently-updated of 7 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Overweight or Obesity: what the trials found

Semaglutide has been shown to significantly reduce body weight in patients with overweight or obesity. Clinical data demonstrated a mean reduction in body weight of up to -16.9% (p=<0.0001) ³.

A high proportion of participants treated with Semaglutide achieved clinically significant weight loss milestones, specifically reaching 5% or more body weight reduction (p=<0.0001) ³.

Recent results — preliminary, needs further review

The 'Go Healthy' program was evaluated in a study involving 580 participants ².
Bimagrumab demonstrated significant reductions in body weight at week 48, with results ranging from -3.31% to -14.24% (p=<0.001), and associated decreases in body fat percentage ⁴.
Bimagrumab was associated with a reduction in waist circumference of ≥5 cm in between 47.1% and 81.9% of participants at week 48 ⁴.
The Diabetes Prevention Program was evaluated in a small cohort (N=60) ¹.
An intensity-based goals intervention showed high system usability scores (above 72) for daily goal sessions and Fitbit integration, though results on physical activity enjoyment were varied ⁶.

For the clinician treating this condition

Semaglutide is an established pharmacological option for weight reduction, with a significant percentage of patients achieving at least a 5% reduction in body weight ³.
Bimagrumab shows promise in reducing both total body weight and body fat percentage over a 48-week period, with notable impacts on waist circumference ⁴.

AI synthesis of 5 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.